New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of
stroke in patients with non-valvular atrial fibrillation. Two agents are direct factor Xa …

Background—Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral
factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in …

New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been
developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients …

BACKGROUND: Warfarin had been the only oral anticoagulant for stroke prevention in
patients with atrial fibrillation (AF) for decades. Direct thrombin inhibitors and factor Xa …

Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …

Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and
edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke …

Background There are no head-to-head randomized controlled trials comparing different
direct oral anticoagulants (DOACs). Thus, we systematically reviewed and meta-analyzed …

Objectives: This study sought to perform an indirect comparison analysis of dabigatran
etexilate (2 doses), rivaroxaban, and apixaban for their relative efficacy and safety against …

Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …